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INTRODUCTION
Remifentanil, a full µ-opioid receptor agonist, is an efficacious and reliable analgesic used in surgery, and it plays a very important role in modern anaesthesia. However, growing evidence has suggested that remifentanil results in postoperative pain and agitation in patients and even affects circulation and respiration (Angst and Clark, 2006) . Moreover, remifentanil has become the major source of opioid-induced hyperalgesia (OIH). The β-blocker propranolol and paracetamol and parecoxib can reportedly treat remifentanil-induced postoperative hyperalgesia (RIPH) (Chu et al., 2012; Troster et al., 2006; Yalcin et al., 2012) . Importantly, low doses of ketamine have remained a common choice in clinical practice (Choi et al., 2015; Hong et al., 2011; Joly et al., 2005; Koppert et al., 2003; Liu et al., 2012; Luginbuhl et al., 2003; Wu et al., 2015) . However, the mechanisms of ketamine in relieving this type of pain have not yet been fully elucidated. According to widespread agreement, OIH processing occurs through the over activation of NMDA receptors (NMDARs) , and as such, it can be counteracted by blocking the relevant calcium channel by reducing the activity of some of its effectors, such as CaMKII, PKC, NO synthase (Chen et al., 2010; Li et al., 2017) , and GSK3β , or by diminishing NMDAR activity via AMPA receptors or delta-opioid receptors . It has been shown that remifentanil shares a mechanism similar to that of OIH. Ketamine, an NMDAR antagonist, blocks the NMDAR channel and acts as an adjuvant analgesic to opioids (Subramaniam et al., 2004) . Importantly, ketamine is an anti-hyperalgesic agent in different models of pain induced by NMDAR activation . However, whether NMDAR is the only target of ketamine in relieving OIH remains unclear. The established process of pain involves the spinal cord and is shaped by the balance of excitatory and inhibitory signals from the brain stem. However, over the past decades, an extensive cortical network associated with pain processing has been revealed. This network includes the anterior cingulate cortex, agranular insular cortex, primary (SI) and secondary somatosensory (SII) cortices, ventrolateral orbital cortex and motor cortex (Xie et al., 2009) . A recent fMRI study also suggested that remifentanil reduced heat pain thresholds and increased neuronal responses in pain encoding regions as well as in key regions of the descending pain modulatory system, such as in the periaqueductal grey matter, nucleus cuneiformis and rostral ventromedial medulla (Sprenger et al., 2018) . The SI and SII cortices constitute the lateral pain system, which is involved in nociception modulation in the descending pain modulatory system. Evidence implicates the SI region as a site for the integration of input from different afferent sources and could account for many of the subjective characteristics (qualitative features) of pain (Nielsen and Arendt-Nielsen, 1998; Yarnitsky and Ochoa, 1990) . However, there is no report regarding whether the SI region is involved in RIPH and the effect of ketamine. Calcium/calmodulin-dependent protein kinase II alpha (CaMKIIα), as a major CaMKII isoform expressed in the central nervous system, is a multifunctional serine/threonine protein kinase (Griffith, 2004) . CaMKIIα and the µ-opioid receptor co-localize in distinct pain-processing brain regions, including the superficial layers of the spinal cord dorsal horn and dorsal root ganglia, and in some neurons of the posteromedial cortical amygdaloid nucleus and the central amygdaloid nucleus (Bruggemann et al., 2000) ; CaMKIIα is required for the initiation and maintenance of OIH. As a primary somatosensory cortex, the cortical SI area is a region with high CaMKIIα expression, which is closely related to RIPH in rat models (Cui et al., 2016; Wang et al., 2013) . However, whether the effect of ketamine on RIPH involves CaMKIIα in the cortical S1 region is unclear. Therefore, we hypothesized that ketamine can alleviate RIPH by decreasing the phosphorylation of CaMKIIα (p-CaMKIIα) and interacting with CaMKIIα and NMDAR in the SI region. In the present study, we used a mouse model of RIPH (Celerier et al., 2006) and investigated whether the role of ketamine in RIPH involves CaMKII and NMDAR. approved by the Institutional Animal Care and Use Committee of Zhejiang University and the International Association for the Study of Pain (Zimmermann, 1983) . All animal studies are reported in accordance with the ARRIVE guidelines (Kilkenny et al., 2010) , and carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986, and associated guidelines, EU Directive 2010/63/EU for animal experiments (www.legislation.gov.uk/ukpga/1986/14/contents) . RIPH was established as described previously (Cabanero et al., 2009; Celerier et al., 2006; Lu et al., 2015) . Briefly, mice were anaesthetized with sevoflurane (surgery, 2%; induction, 3%) via a nose mask, and a 0.7-cm longitudinal incision was made on the left hind paw from the proximal edge of the heel extending towards the toes. Then, we sutured the incision and used remifentanil (0.04 mg/kg) to induce hyperalgesia immediately with a subcutaneous infusion for 30 min using a syringe pump (RWD life science, Shenzhen, China). The infusion rate was 2 ml/h. The timeline for the experiment is summarized in Figure 1 . Ketamine (1.4, 2.1, and 2.8 mg/kg) was dissolved in saline and infused subcutaneously together with remifentanil for 30 min using a syringe pump. Control animals received the same volume of saline under identical conditions. The NMDAR activator NMDA, the CaMKII inhibitor KN93, and the CaMKII activator BayK8644 were dissolved in 1% DMSO and adjusted to a volume of 5 µl. The intrathecal injection performed 30 min before surgery was as described in a previous study (Alier et al., 2008) . The experimental groups and the number of animals used for each set of experiments (N) are indicated in Table 1 and in the figure legends. 
Behavioural tests 2.3.1 Determination of the paw withdrawal mechanical threshold (PWMT)
Mechanical sensitivity was measured using von Frey filaments according to the "up-down" paradigm (Luo et al., 2008) . In brief, the mice were placed in individual resin containers with a wire mesh bottom. After 30 min of acclimation, von Frey filaments were applied upward through wire mesh to the mid-plantar of the left hind paw for 3 s or until paw withdrawal was observed. The up-down algorithm was used to determine the 50% probability of the paw withdrawal threshold.
Determination of the paw withdrawal thermal latency (PWTL)
Thermal sensitivity was assayed using a hot plate as described previously (Zimmer et al., 1999) .
The mice were placed on a hot plate with a temperature of 55.5±0.5°C. The time for the mice to withdraw their hind paws was used as the paw withdrawal latency. The cut-off was set at 30 s to avoid tissue damage. Tests were repeated with at least 5-min intervals, and the mean values were calculated.
Western blotting
After treatment, the mice (n=6 per group) were sacrificed by decapitation at 0 (before), 0.5, 2 and 5 h after the experimental procedures, and the S1 region was quickly dissected and frozen in liquid nitrogen. Tissue samples were homogenized in cold RIPA buffer (Boster, Wuhan, China) containing 1×PhosSTOP (Roche, Basel, Switzerland), 1% protease inhibitors (Roche) and 2% PMSF (Boster). The samples were centrifuged at 12,000 rpm for 10 min at 4°C. The protein concentration of each extract was determined using a Bio-Rad Protein Assay (Bio-Rad. Lake Franklin, USA). The protein samples were denatured at 100°C for 5 min in 5X SDS-PAGE Sample Loading Buffer (Beyotime, Haimen, China). Samples containing 30 µg of protein were electrophoresed in 8% SDS-PAGE (70 V, 60 min, then 130 V, 45 min) and transferred onto NC membranes (Schleicher & Schuell, Germany) (300 mA, 1 h) using a Mini-PROTEA II system (Bio-Rad. Lake Franklin, USA). The membranes were incubated for 1 h at room temperature with TBS containing 5% BSA to block nonspecific binding and then incubated overnight at 4°C with primary antibodies. The antibodies used were as followed: anti-p-CaMKIIα antibody (sc-32289, 1:1000, Santa Cruz, USA), anti-CaMK IIα antibody (sc-13141, 1:1000, Santa Cruz, USA), anti-GAPDH antibody (sc-47778, 1:2000, Santa Cruz, USA), anti-NR2B antibody (21920-1-AP, 1:2000, Proteintech, USA) and anti-pNR2B (S1303) antibody (ab81271, 1:2000, Abcam, UK). After three washes with TBST, the membranes were incubated at room temperature for 1 h with IRDye 800CW goat anti-rabbit IgG (926-68071, LI-COR, USA) or IRDye 680CW goat anti-mouse IgG (926-32210, LI-COR, USA) at a 1:5000 dilution and then imaged and analysed with LI-COR's Odyssey Infrared Image System (LI-COR, USA).
Fluorescence immunohistochemistry
Post-fixed brains were embedded in paraffin, and 4-μm slides were prepared with a microtome (Leica, Bayern, Germany). To detect p-CaMKIIα expression levels in the cortex, we first subjected the slides to heat-induced epitope retrieval treatment. Briefly, we used a water bath set to 100°C and incubated the slides in citrate buffer for 30 min. Then, the slides were incubated with a primary antibody against p-CaMKIIα (Thr286) (sc-32289, Santa Cruz, California, USA) at a dilution of 1:500 overnight at 4°C. This antibody can selectively recognize the Thr286 phosphorylation site of CaMKIIα in humans, rats and mice. Then, the slides were incubated at room temperature for 30 min and washed with PBS 3 times. Next, the slides were incubated with DyLight488-conjugated secondary antibodies (1:500, Jackson Immuno Research, West Grove, USA) for 30 min at 37°C. The slides were then washed three times, stained with DAPI at room temperature for 5 min, rinsed with water for 5 min, and mounted with fluoromount (KeyGEN Biotech, Nanjing, China). Images were captured with a confocal fluorescence microscope imaging system (Olympus, Okaya, Japan). A blinded experimenter capture three selected fields for every slide under 10×40 magnification and used ImageJ software (homepage: http://imagej.nih.gov/ij/) to count the number of positive cells.
Statistical analysis
The data and statistical analysis comply with the recommendations for experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as the mean±SE. The statistical analyses were performed in GraphPad Prism Version 5 software (La Jolla, CA, USA) using a two-way analysis of variance (ANOVA) with repeated measures and post hoc multiple pairwise comparison Bonferroni tests. For all tests, a p value < 0.05 was considered statistically significant.
RESULTS

Ketamine inhibited RIPH
The PWMT and PWTL in the incision group were slightly decreased after surgery, indicating that the incision itself did induce sensory hypersensitivity. However, compared with the incision, remifentanil (0.04 mg/kg) significantly reduced the PWMT and PWTL in mice at 0.5 h, 2 h, and 5 h postoperatively (P <0.05, Fig. 2A and 2B ), indicating the presence of RIPH. Hyperalgesia appeared at 0.5 h after treatment with remifentanil, peaked at 2 h postoperatively, and recovered at 24 h. In contrast, ketamine (2.1 mg/kg) completely restored the PWMT and PWTL to baseline levels at 0.5 h and 2 h ( Fig. 2A and 2B) . To investigate the effect of ketamine on RIPH, we used three different doses of ketamine (1.4, 2.1, 2.8 mg/kg). Ketamine dose-dependently reversed the reduction in the PWMT and PWTL at 0.5 h, 2 h and 5 h (P <0.05 versus the R group). Moreover, ketamine (2.8 mg/kg) significantly increased the PWTL above the baseline measurements. A single low dose of ketamine did not induce analgesia in animals not treated with the opioid. Therefore, one possible explanation is that a high dose of ketamine extends the analgesic effects of remifentanil because NMDA antagonism enhances opioid analgesia. Another possibility is that ketamine induces analgesic effects per se because ketamine (2.1 mg/kg) alone can improve the induction of sensory hypersensitivity in the incision itself. Therefore, these behavioural data suggest that ketamine can reverse RIPH. Ketamine (2.1 mg/kg) completely restored the PWMT and PWTL to baseline levels at 0.5 h and 2 h ( Fig. 2A, 2B) ; therefore, this dose was selected for subsequent experiments. 
Ketamine decreased remifentanil-induced phosphorylation of CaMKII in the S1 region
To investigate whether RIPH and ketamine affect CaMKIIα activity in the S1 region, we determined the phosphorylation of CaMKIIα (p-CaMKIIα) at the Thr286 site. At 0.5 h, 2 h, and 5 h, p-CaMKIIα was significantly higher in the S1 region of RIPH mice than in that in the control incision mice (P <0.05). Ketamine (2.1 mg/kg) did not affect p-CaMKIIα in the S1 region after surgery, but ketamine (2.1 mg/kg) significantly decreased p-CaMKIIα levels in the S1 region in the RIPH model (P<0.05 vs the R group) ( Fig. 3 ). No significant difference was observed in the total CaMKIIα protein expression among the groups. The maximum level of p-CaMKIIα was achieved at 2 h postoperatively, consistent with behavioural experiments; thus, 2 h after surgery was selected as the checkpoint for the following experiments. No significant difference was observed in p-CaMKIIα-positive cells in the S1 region in the KM group compared with that in the incision group (P >0.05) (Fig.4) . In the RIPH model, the numbers of p-CaMKIIα-positive cells in the S1 region were significantly increased, while in the RKM group, the numbers of p-CaMKIIα-positive cells were significantly reduced (P<0.05 vs the R group). Based on these results, CaMKIIα phosphorylation is involved in the inhibition of RIPH by ketamine in mice. Moreover, ketamine selectively antagonized the remifentanil-induced phosphorylation of CaMKIIα, without affecting CaMKIIα phosphorylation under normal conditions. 
BayK8644 reversed the effect of ketamine on RIPH
To further determine whether ketamine directly inhibits CaMKIIα activity, we first treated mice with BayK8644, a selective CaMKII activator. We found that compared with incision alone, BayK8644 dose-dependently decreased the PWMT and PWMLat 0.5 h, 2 h, and 5 h, and the effect of high dose BayK8644 was similar to that of the RIPH model ( Fig. 5A and B) . Therefore, activating CaMKIIα by BayK8644 can directly induce hyperalgesia. In the RIPH model, ketamine (2.1 mg/kg) completely returned the PWMT and PWTL to baseline levels, but in mice co-treated with ketamine and a high dose of BayK8644, the PWMT and PWTL were significantly decreased at 0.5 h, 2 h, and 5 h (P < 0.05 vs the RKM group), and there were no significant differences compared with those of the R group (P > 0.05) ( Fig. 5C and D) . These results demonstrated that the ability of ketamine to reduce RIPH is blocked by the addition of BayK8644.These results support our hypothesis that CaMKIIα activation is involved in hyperalgesia, and this effect is mitigated by ketamine in RIPH. 
KN93 enhanced the effect of ketamine in RIPH
To further determine whether ketamine mitigated RIPH by inhibiting the activity of CaMKIIα, we used KN93, a CaMKII inhibitor. KN93 dose-dependently increased the PWMT and PWTL in RIPH mice at 0.5 h, 2 h and 5 h (P< 0.05 vs the R group) ( Fig. 6A and B) , and the tendencies were similar to those of ketamine. A lower dose of KN93 reversed the PWMT and PWTL to the levels of the incision group, and a medium dose of KN93 reversed the PWMT and PWTL to baseline levels; therefore, we selected this dose for the next experiment. When we co-treated RIPH mice with ketamine and a medium dose of KN93, the PWMT and PWTL were significantly higher than those of the RKM group at 0.5 h, 2 h and 5 h (P < 0.05), as well as higher than those at baseline ( Fig. 6C  and 6D) . These results further supported our hypothesis that CaMKIIα inhibition can attenuate hyperalgesia, which was enhanced by ketamine via CaMKIIα in RIPH. 
NMDA reversed the effect of ketamine in RIPH
Ketamine also reportedly non-competitively inhibits NMDARs. Therefore, we first employed NMDA, an NMDAR agonist, to confirm this effect. The PWMT and PWTL in the NMDA group were significantly decreased at 0.5 h, 2 h, and 5 h (P < 0.05) compared with those in the incision group, and these data were similar to those observed in the RIPH model. These results suggested that NMDA can also directly induce hyperalgesia. When we treated RIPH mice with NMDA, the PWMT and PWTL decreased to a greater extent at 0.5 h, 2 h, and 5 h (P > 0.05 vs the R group). Additionally, when we treated RIPH mice with ketamine and NMDA, the PWMT and PWTL were significantly decreased in the RKM+NMDA group compared with those in the RKM group (P < 0.05) ( Fig. 7A and B) . These data suggested that NMDA can directly induce hyperalgesia, enhance RIPH and reverse the effect of ketamine. These results further supported our hypothesis that both NMDARs and CaMKIIα are involved in RIPH and the effect of ketamine on RIPH. 
Phosphorylation of CaMKIIα and NR2B is involved in RIPH
We further determined the levels of p-CaMKIIα and p-NR2B in the SI region. Remifentanil increased the levels of p-CaMKIIα and p-NR2B when compared with the control incision group (P < 0.05 vs the I group), while ketamine decreased remifentanil-induced p-CaMKIIα and p-NR2B levels (P < 0.05 vs the R group). BayK8644 also increased the phosphorylation of CaMKIIα and NR2B, similar to remifentanil, while in the RKM+ BayK8644H group, the phosphorylation of CaMKIIα and NR2B was decreased compared with that in the RKM group (P < 0.05) ( Fig. 8A-C) . These data suggested that the effects of ketamine on p-CaMKIIα, total NR2B protein, and p-NR2B were reversed by the calcium channel activator BayK8644. KN93, a CaMKII inhibitor, decreased the p-CaMKIIα, total NR2B protein, and p-NR2B levels in the RIPH model, and when combined with ketamine, the effects were significant ( Fig. 8A-C) . These data confirmed our hypothesis that ketamine mitigated RIPH by affecting the activity of CaMKIIα. Figure 8. KN93, BayK8644 and NMDA affects the p-CaMKIIα α α α and S1303 levels in the S1 cortex of the RIPH model. (A) Typical western blot results. (B-C) Semi-quantitative analysis of p-CaMKIIα, total CaMKIIα, S1303 and NR2B levels in the S1 cortex of mice 2 h after treatment with KN93 or BayK8644.
(D) Typical western blot results. (E-F) Semi-quantitative analysis of p-CaMKIIα, total CaMKIIα, S1303 and NR2B levels in the S1 cortex of mice 2 h after treatment with NMDA. NR2B used as the NMDA receptor form, S1303 used as its activated site of pNR2B. The results were expressed as the mean ± SE;
and conducted by using a two-way analysis of variance (ANOVA) with repeated measures. a: P< 0.05 versus the I group, b: P< 0.05 versus the RKM group, c: P< 0.05 versus the R group, n = 3 per group.
To further investigate the effect of the NMDA receptor, we determined the expression levels of p-CaMKIIα and p-NR2B in the R+NMDA, NMDA and RKM+NMDA groups. NMDA itself did not significantly affect the phosphorylation of CaMKIIα and NR2B, but the levels in the R+NMDA group were significantly higher than those in the R group (P < 0.05). In addition, the levels were significantly higher in the RKM+ NMDA group than in the RKM group (P < 0.05) ( Fig. 8D-F) . These data suggested that NMDA can enhance the phosphorylation of CaMKIIα and NR2B in the RIPH model. Thus, these findings confirmed that both CaMKIIα and NMDAR participated in RIPH and were involved in the effect of ketamine.
DISCUSSION
In our study, we explored the mechanism of ketamine in RIPH after surgery. The behaviour test results showed that remifentanil can induce postoperative hyperalgesia and that ketamine can alleviate RIPH. Remifentanil (0.04 mg/kg) significantly increased the phosphorylation of CaMKIIα at Thr286 in the SI region, while ketamine decreased p-CaMKIIα. The calcium channel agonist BayK8644 and NMDA reversed the alleviating effect of ketamine in RIPH, while the CaMKII inhibitor KN93 enhanced the effect of ketamine in RIPH. Further experiments suggested that ketamine may downregulate CaMKIIα phosphorylation, total NMDAR protein and NMDAR phosphorylation levels in the S1 region. KN93 may enhance these effects, and NMDA and BayK8644 may reverse them. Therefore, our experimental results showed that ketamine may alleviate RIPH by decreasing CaMKIIα phosphorylation, total NMDAR protein and NMDAR phosphorylation levels in the SI region and that the mechanism of ketamine may involve both CaMKIIα and NMDAR.
The cerebral cortex was not initially thought to be involved in pain perception, but over the past decades, an extensive cortical network associated with pain processing has been revealed (Xie et al., 2009) . Additionally, evidence has implicated SI as a site for the integration of input from different afferent sources, leading to the perceptual recognition of pain (Vierck et al., 2013) . Ketamine is arguably the most important advancement in the field of psychiatry due to its rapid antidepressant effects in the past half century (Berman et al., 2000) . Recent rsfMRI studies have evaluated the antidepressant effects of ketamine involved in reducing connectivity in the bilateral dorsal prefrontal cortex (DPFC) network in patients (Arnsten et al., 2016; Driesen et al., 2013; Gass et al., 2014; Scheidegger et al., 2012) . Subanaesthetic doses of S-ketamine (5, 10, and 25 mg/kg, s.c.) decrease the functional connectivity of the DPFC region to the pregenual anterior cingulate and medioprefrontal cortex via its representative hub, the posterior cingulate cortex in rats (Gass et al., 2014) . Recent studies also suggested that ketamine inhibits central sensitization and prevents OIH (Liang et al., 2012) , as well as suppresses the hyperactivity of neurons in the anterior cingulate cortex to produce anti-aversive effects (Zhou et al., 2018) . Thus, we selected the SI, a pain encoding region, to study the effect of ketamine. Future studies are also needed to examine additional brain regions, such as the anterior cingulate cortex, to confirm the effect of ketamine in RIPH.
Regarding the dose of ketamine in RIPH, previous studies suggested different ranges from 0.5 mg/kg (Choi et al., 2015) and 20 mg/kg (Hayashi et al., 2011) to 50, 100, and 150 mg/kg ). Dossat, A.M. et al defined a low dose of ketamine as 0.5 mg.kg to 3 mg/kg (Dossat et al., 2018) . For our test doses of ketamine (1.4, 2.1, and 2.8 mg/kg) , the mice were in an awake state, and the righting reflex was present. A rotarod test (Shown in Supplemental data) confirmed that the low and medium doses of ketamine did not induce overt sedation and anaesthesia because they did not affect the mouse's latency to fall, but the high dose may have a slight sedative effect. Therefore, in this study, we selected a medium dose of ketamine, 2.1 mg/kg.
NMDARs have been suggested to play a crucial role in the central sensitization of hyperalgesia (Zhao and Joo, 2008) , and ketamine is considered a non-competitive NMDAR antagonist that can reduce hyperalgesia through NMDARs (Choi et al., 2015) . Gu et al. confirmed that tyrosine phosphorylation of NR2B at Tyr1472 in the spinal dorsal horn contributes to RIPH and that ketamine can attenuate this effect (Gu et al., 2009 ). However, whether ketamine works by only blocking NMDAR activation and is not involved in other signalling pathways remains uncertain. CaMKIIα is an important molecule in neural plasticity changes (Fink and Meyer, 2002) , while hyperalgesia reflects a change in neural plasticity (Woolf and Salter, 2000) . Moreover, CaMKIIα is an effector of both excitatory glutamate (Coultrap et al., 2011) and µ-opioid receptors (Bruggemann et al., 2000) . A previous study confirmed that CaMKIIα was required to initiate and maintain OIH (Chen et al., 2010) and may even be involved in changes in the transition from acute pain to chronic pain (Ferrari et al., 2013) . Increased intracellular Ca 2+ levels and activated calmodulin can activate CaMKII, leading to its autophosphorylation, which does not depend on Ca 2+ for activation (Miller and Kennedy, 1986) . The autophosphorylation of CaMKII has been shown to enhance calcium signals and plays an important role in modulating synaptic plasticity and central sensitization (Fang et al., 2002; Lucchesi et al., 2011) .
Previous studies have suggested that remifentanil acting on the cortical S1 region activated NMDAR through a cell signal transduction pathway, probably leading to calcium influx into cells to activate CaMKII and ultimately induce hyperalgesia . Remifentanil diminishes the presence of the µ-opioid receptor in the neural plasma membrane, and this change positively influences the appearance of OIH (Lu et al., 2015) . Moreover, remifentanil (0.04 mg/kg) can increase the phosphorylation of CaMKIIα in the cortex of the central nervous system, hippocampus and spinal dorsal horn, resulting in hyperalgesia (Chen et al., 2010) . Intrathecal injection of a CaMKII inhibitor, KN93, increased the nociceptive thresholds of the PWMT and PWTL in a dose-dependent manner in an RIH model (Jiang et al., 2015) . Knock-out of the Tyr1472 phosphorylation site in the NR2B subunit can reduce the activation of CaMKII, thus relieving neuropathic pain (Matsumura et al., 2010; Zhou et al., 2007) . Regarding the relationship between CaMKIIα and NMDARs, many studies have suggested that CaMKIIα and NMDARs may form complexes that play an important role in cerebral ischaemia or other neurological models (Matsumoto et al., 2013; Wang et al., 2014) . Changes in NR2B and CaMKII have also been observed in neural plasticity studies (Sanhueza et al., 2011) , but whether they also have effects on RIPH remains unclear.
In our study, NMDA receptor agonists, CaMKII inhibitors, and calcium channel agonists were used to explore the relationship between CaMKIIα and NMDARs in RIPH. First, we found that the NMDA receptor agonist can induce hyperalgesia, while the NMDAR agonist reversed the effect of ketamine by reducing RIPH. However, the data presented in Fig. 7 , which show that NMDA treatment attenuates the effects of ketamine on RIPH, suggest that the effects of ketamine may not occur directly through NMDAR but rather a subset of receptors. Our additional results indicated that ketamine's effects at the NR2B subunit of NMDAR are specifically involved in the beneficial effects of ketamine in the RIPH model. Second, our behavioural test results showed that BayK8644, an L-type calcium channel activator, can induce hyperalgesia while reversing the effect of ketamine in RIPH. Moreover, ketamine reversed the Bay8644-induced hyperalgesic effect. Interestingly, in some circumstances, BayK8644 also promotes the release of NMDAR activators (Diaz-Trelles et al., 2002; Novelli et al., 2005) , so the mechanism of BayK8644-induced hyperalgesia may also involve NMDAR and CaMKII. Third, CaMKII inhibitors can inhibit RIPH. Moreover, ketamine and CaMKII inhibitors have similar effects on the inhibition of RIPH. KN93 administration at high doses enhanced ketamine's effects in the RIPH model to levels comparable with those achieved with the higher dose of ketamine. These data suggested a synergistic action of the two compounds and that CaMKII is not the sole mediator of ketamine's effect; other mechanisms may be involved.
CONCLUSION
In this study, we demonstrated that CaMKIIα and NMDAR may be involved in RIPH, and CaMKIIα phosphorylation and NMDAR may be involved in the inhibitory effects of ketamine in the S1 region of RIPH mice. The effect of ketamine was reversed by the calcium channel agonist and CaMKII activator BayK8644 or by the NMDA receptor agonist NMDA, while the CaMKII inhibitor KN93 enhanced the effect of ketamine. Moreover, the activity of ketamine involved in the antidepressant and anti-nociceptive effects in the cerebral cortex suggests that the mechanism proposed in our study may be applicable in other neuropsychiatric conditions. Considering the clinical use of ketamine with repeated low dose exposure, the future studies should evaluate repeated ketamine treatments, to determine whether ketamine has a beneficial effect under the conditions established in these preclinical studies.
